[S-35] Symposium 35「Development of treatments for hereditary muscle diseases that Japan is leading」

[S-35-1] デュシェンヌ型筋ジストロフィーに対するRNA治療法の開発

青木 吉嗣 (独）国立精神・神経医療研究センター 神経研究所 遺伝子疾患治療研究部)

Yoshitsugu Aoki, MD, PhD graduated in Medicine from the University of Tohoku, Japan, in 2001, working in clinical Neurology and became a consultant neurologist in 2008 before gaining a doctorate in System Neuroscience in 2011 from Tokyo Medical and Dental University Graduate School (TMDU), Japan. Dr Aoki joined Prof. Matthew JA Wood’s laboratory at the University of Oxford in 2012. The Royal Society of the UK endorsed his achievements in the development of oligonucleotide treatment for neuromuscular diseases as an Exceptional Promise in 2013 and has prepared him to serve as a member of the Congregation and a Senior Research Scientist, Faculty of Physiological Sciences, University of Oxford in 2014. He is currently the Director of the Department of Molecular Therapy and the head of the dystrophic dog facility at the National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP). Dr. Aoki also ranks as Adjunct Professor at several universities, such as TMDU.